Background: Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naïve individuals.
Introduction 54
Plasmodium vivax is the most globally widespread human malaria parasite, and the predominant 55 cause of malaria outside of Africa (1). Although a major cause of morbidity, P. vivax infection has 56 long been regarded as benign compared to P. falciparum. However, it has recently become widely 57 recognised as a cause of severe, life-threatening, and fatal malaria infection (2, 3). As a consequence, 58 there is renewed interest in developing P. vivax specific control and elimination strategies (4). P. 59
vivax is considered more difficult to control than P. falciparum due to the parasite's unique biological 60
features that increase its potential for transmission (5). Unlike P. falciparum, the transmissible stages 61 of P. vivax (the gametocytes) appear early during blood-stage infection before the onset of symptoms, 62 which increases the likelihood of transmission before treatment. P. vivax produces hypnozoites which 63 are dormant liver-stage parasite that cause relapses months to years after initial infectionreported 64 to account for up to 80% of all P. vivax infections (6)thus providing repeated opportunities for 65 onward transmission. In addition, P. vivax can be transmitted by a broad range of Anopheles vectors, 66 many with exophilic and zoophilic tendencies, thus reducing the efficacy of conventional vector 67 control measures (7) . Therefore, as well as treating asexual parasites to control clinical illness, P. 68 vivax control strategies must also target hypnozoites and block transmission to have a significant 69 impact on control and elimination (8) . 70
The current recommended treatment for P. vivax is chloroquine or artemisinin-based combination 71 therapy to clear asexual parasitaemia, administered with the 8-aminoquinioline, primaquine for 14 72 days to clear liver-stage hypnozoites (9) . A single dose of tafenoquine recently demonstrated 73 equivalent efficacy against hypnozoites with the potential to substantially improve treatment 74 compliance. However, wide scale deployment of these drugs to achieve meaningful public health 75 impact is complicated by the need to screen for glucose-6-phosphate dehydrogenase deficiency, and 76 safer alternatives are needed (10). 77
A P. vivax transmission-blocking vaccine (TBV) could interrupt transmission from primary 78 infections, relapses, and also asymptomatic infections that remain undiagnosed and transmissible for a prolonged period. A TBV would reduce morbidity and mortality by preventing both new clinical 80 infections and hypnozoite formation (11, 12) . The inability to continuously culture P. vivax parasites 81 in vitro, and the difficulties in using animal models (8) 
Results

105
Twenty-six malaria-naïve volunteers were enrolled in two clinical trials: Study 1 (n=2) undertaken 106 from October 8, 2014 to January 8, 2015 and Study 2 (n=24) undertaken from February 22, 2016 to 107 May 21, 2017 ( Figure 1 and 2). Baseline characteristics of participants are presented in Table 1 . 108
All participants were inoculated with an estimated 564 viable P. vivax parasites and the experimental 109 infection was generally well tolerated. In Study 1, 14 adverse events (AEs) were reported: 12 110 attributed to malaria (headache, fever, myalgia, arthralgia, presyncope, rigors), one deemed possibly 111 related to artemether-lumefantrine (somnolence), and one not related to malaria or artemether-112 lumefantrine (headache 49 days after treatment) ( Table 2 ). Most AEs resolved within 24 h of 113 treatment with paracetamol, except two intermittent headaches that resolved in 4 days and 8 days, and 114 right knee pain that resolved in 4 days. All AEs were mild (n=13/14; 92.9%) or moderate (n=1/14; 115 7.1%) in severity. In Study 2, 355 AEs were reported (Table 2) . A total of 296 (83.4%) were related to 116 malaria, of these, 8 (2.3%) were concurrently deemed possibly related to chloroquine. Eleven (3.1%) 117
AEs were related to direct skin feeding (DFA) (reaction at site of mosquito bite); the remaining AEs 118 were attributed to other causes. Most AEs were mild (250/355; 70.4%) or moderate (98/355; 27.6%) 119 in severity. Four severe AEs occurred and were all attributed to malaria: reduced neutrophil count 120 (0.65 ×10 9 /L), chills, elevated alanine aminotransferase (peak 6.9 ×ULN), and arthralgia. No serious 121
AEs were reported in either trial. 122
All 26 participants developed blood-stage parasitaemia. In Study 1, parasites were first detected by 123 18S quantitative PCR (18S qPCR) on Day 5 in both participants. Parasitaemia peaked at 21,836 and 124 8,949 parasites/mL on the day of treatment (Day 8), and was completely cleared following treatment 125 with artemether-lumefantrine ( Figure 3A ). In Study 2, parasites were first detected by 18S qPCR in 126 21/24 participants on Day 4, and in the remaining 3 participants on Day 5. The course of parasite 127 development did not differ between cohorts ( Figure 3D+F ) and parasitaemia was cleared in all 128 participants in a median of 3 days after initiation of chloroquine treatment, range = 1.5-7.0 days. 129 Gametocytes were first detected (above 10 gametocytes/mL) on Day 6 in Study 1 ( Figure 3A) and 130 between Day 4 and 7 in Study 2, which was an average of 1·5 days (range = 0-3 days) after first 131 detection of asexual parasites ( Figure 3D -F). Using the transcript number estimates per gametocyte 132 published by Karl et al., (18) to convert pvs25 transcripts/mL to gametocytes/mL, the peak 133 gametocyte levels were 5.5% (median) of the peak asexual parasite levels and gametocytemia 134 correlated with asexual parasitemia (p<0.0001) ( Figure 3C ). The course of gametocytemia followed 135 the asexual parasitaemia, but in Study 2 after chloroquine treatment, in contrast to immediate 136 clearance of asexual parasites, clearance of gametocytes was delayed a further 24 h. 137
In Study 2 cohort 1, median gametocytemia was 136 gametocytes/mL at the time of treatment/last 138 mosquito feeding assay, meaning only 0.14-0.68 gametocytes would be imbibed in a 1-5µL mosquito 139 blood-meal, making transmission extremely unlikely. As a consequence, following review of the 140 safety data and approval from the Safety Monitoring Committee the recommendation was made to 141 delay treatment until Day 10 in cohorts 2 and 3. This resulted in significantly higher median 142 gametocytemia at the time of treatment/last mosquito feeding assay (2,351 gametocytes/mL; 143 p<0.0001) compared to participants in cohort 1 ( Figure 3B ). 144
The optimal times for mosquito feeding were Day 9 and 10, when 69% (11/16) of participants were 145 infectious to mosquitoes (Table 3 and Table S6 ). Participants were not infectious on Day 6 and 7 146 (0/8), and only one participant was infectious on Day 8 (1/8). The rate of mosquito infection was 147 highest on Day 10 ( Figure 4A ; median on Day 10 = 5.2%; IQR 2.8-8.9). Direct skin feeding resulted 148
in higher mosquito infection rates (median = 3.3%; IQR 2.9-6.1) than direct membrane feeding with 149 whole blood (median = 1.8%; IQR 1.2-2.8; p = 0.04), and membrane feeding with serum replacement 150 (median = 8.6%; IQR 2.8-13.9) also resulted in significantly higher mosquito infection rates than 151 membrane feeding with whole blood (p = 0.02) ( Figure 4B and Table S6 ). Successful mosquito 152 transmission was associated with gametocyte density, with gametocytemia being significantly higher 153 in the infectious samples (median = 1,993 gametocytes/mL) compared to the non-infectious samples 154 (median = 136 gametocytes/mL; p<0.0001) ( Figure 4C ).
To increase mosquito infection rates in this model, we enriched gametocytes over a percoll gradient 156 either ~10 or ~40 fold to increase the density of gametocytes offered to mosquitoes in the membrane 157 feeding assays (19). Very high levels of mosquito infection ranging from 26% (Day 9) to 92% (Day 158 10) were achieved following ~10 fold enrichment (Table 4 ). When gametocytes were enriched ~40 159 fold, the mosquito infection rate was 97%, with a mean of 7 oocysts (range 1-16) per midgut. 160
Salivary gland sporozoites were detected 15 to 17 days after the feeding assay, with an average of 161 7,635 sporozoites per mosquito following ~40 fold enrichment (Table 4 ). To assess viability, these 162 sporozoites were collected from the mosquitoes and incubated with HC-04 hepatocyte cells in culture. 163
Following 7 days of incubation, liver-stage schizonts were observed by staining the cells with UIS4 164 monoclonal antibody ( Figure 4D ). Gametocytemia was detected in all participants and appeared in circulation early during blood-stage 181 infectiononly 1 to 2 days after the first appearance of asexual parasitesconsistent with reports 182 of a shorter gametocyte maturation time for P. vivax compared to P. falciparum (14, 15) . The majority 183 of participants (11/16; 68·8%) were infectious to laboratory reared An stephensi mosquitoes on Day 9 184 and 10 after infection. This represents the first report of efficient P. vivax gametocyte transmission 185 during experimental malaria infection. Transmission from humans to mosquitoes was previously 186 attempted during a sporozoite induced P. vivax experimental malaria infection study but was 187 unsuccessful despite detection of the pvs25 gametocyte marker (20, 21). In our previous P. vivax 188 IBSM study (15) the peak gametocytemia was 43 gametocytes/mL compared to 47,393 189 gametocytes/mL in this study (Supplementary p 19) . Difficulty was experienced during the previous 190 study with verification of mosquito infection by microscopy. Review of the photomicrographs by a 191 number of expert oocyst microscopists from different laboratories indicated a lack of consensus about which, if any, were true oocysts and which were artefact. This ambiguity about the identification of 193 mosquito infection led us to develop and validate the qPCR assay used here for high-throughput, 194 sensitive, and accurate evaluation of midgut infection (22). It was also followed by a study detailing 195 the difficulty with oocyst identification by microscopy (23). Moreover, similar structures identified 196 later in the same QIMR laboratory were confirmed PCR negative. Although we are unable to verify 197 by PCR the result of the previous study with the Solomon Island isolate, we believe based on the lack 198 of consensus about the identification of oocysts together with the very low gametocytemia during that 199 study that it is likely the mosquito infection rate reported was an overestimate. The study presented 200 here thus demonstrates higher levels of gametocytemia, reliable transmission to mosquitoes, and 201 increased assay validity. The mosquito infection rates we observed in this current study (1-18%) are 202 comparable to those reported from asymptomatic natural gametocyte carriers who had a mean 203 gametocyte density of 1,323 gametocytes/mL and an average mosquito infection rate of 4.2% (21). 204
We also observed increasing mosquito infection rates with increasing gametocytemia, consistent with 205 data from natural infections (21, 24). Transmission was low (on Day 8) or did not occur (on Day 6 206 and 7) before Day 9, likely due to the low gametocyte densities at the time of feeding. Gametocytemia 207 was so low (less than 397 gametocytes/mL) that the chance of gametocytes being taken up in a 1-5 208 µL blood meal was extremely unlikely. Membrane feeds performed with gametocytes that had been 209 enriched over a percoll gradient resulted in very high levels of transmission, further demonstrating the 210 observed relationship between gametocyte density and transmission success. 211
Our model provides a new platform to fully evaluate factors governing efficient transmission, and in 212 accordance with previous P. vivax studies, mosquito infection rates were higher via the natural route 213 of infection compared to feeding mosquitoes on whole blood via a membrane (25, 26). This is 214 potentially due to conditions during membrane feeding being suboptimal for efficient transmission, or 215 because gametocytes may localise to subdermal capillaries for more efficient uptake. Consistent with 216 previous reports (19, 26), we observed higher mosquito infection rates from membrane feeding with 217 serum replacement than from direct membrane feeding on whole blood. This suggests a component of 218 the venous blood sample not present in vivo during skin feeding, such as anticoagulant, may inhibit 219 transmission (19, 26, 27) . 220
Mosquito infection rates were very high after membrane feeding with enriched gametocytes, which 221 further supports the association between gametocyte density and transmission. Midgut oocyst 222 infections developed into salivary gland sporozoites, and these sporozoites were able to infect and 223 develop in human hepatocytes in vitro. This demonstrates the potential application of this model to 224 facilitate the study of P. vivax liver-stages. negative for blood-borne pathogens using a Red Cross donation protocol and the RBCs were 255 cryopreserved as described previously (14). The cryopreserved bank tested negative for adventitious 256 agents and was subject to whole genome sequencing (28). 257
Each inoculum was prepared by aseptically thawing and washing a vial of cryopreserved RBCs and 258 diluting to 2 mL with injectable saline. Table  268 S4). All participants were confirmed parasite negative at the end of study ( Figure 1+2) . 269
For Study 2, infectivity of gametocytes was evaluated using mosquito feeding assays between Day 6 270 and 8 (cohort 1) or on Day 9 and 10 (cohorts 2 and 3). All feeding assays were performed before drug 271 treatment was initiated. Gametocytes were fed to Anopheles stephensi mosquitoes via direct skin 272 feeding assays (DFAs; 2 per participant), direct membrane feeding assays with whole venous blood in 273 lithium heparin anticoagulant (DMFAs; 2-3 per participant), or membrane feeding assays with serum 274 replacement (MFA-SR) (19). Exploratory membrane feeding assays were performed to investigate 275 mosquito infection rates when fed on gametocytes enriched from participants' blood over a percoll 276 gradient (Supplementary p 17) . We determined transmission to mosquitoes by measuring midgut 277 oocyst infections using the 18S qPCR assay (14, 22) . Microscopy was used to visually confirm 278 oocysts in a small random selection of midguts prior to qPCR ( Figure S3A+B ). Salivary gland 279 sporozoite infections were assessed using microscopy 15 to 17 days after mosquito feeding (Figure 280 Prevalence of mosquito infection in successful feeding assays, by feeding assay type (n=37). Groups compared by Kruskal-Wallis test with Dunn's multiple comparison test. (C) The gametocytemia for participants samples that were infectious compared to samples that were non-infectious (n=54). Groups compared by Mann-Whitney test. Box plots indicate the median and whiskers show the minimum and maximum. (D) Representative image from of a P. vivax liver-stage schizont stained with UIS4 and Hoechst33342 following incubation of sporozoites with HC-04 culture for 7 days (Left panel -white channel (Hoechst33342), middle panel -red channel (Alexa fluor 488-conjugated UIS4 antibody), right panelmerge). Image taken at 40× magnification. Scale bar = 20 µm. Sporozoites were obtained by feeding mosquitoes on enriched gametocytes collected on day 10 from participants in cohort 3 (Supplementary pp 18). DFA = direct skin feeding assay, DMFA = direct membrane feeding assay with whole blood, MFA-SR = membrane feeding assay with serum replacement. Membrane feeding assays were performed with gametocytes enriched over a percoll gradient from blood pooled from all participants in a cohort, at the time point specified. Mosquito infection rate is reported as prevalence of infection (% of mosquitoes infected per feeding assay). NC: not counted. a Day relative to inoculation (Day 0).
